Harrow stock highlights 15 ophthalmic studies at AAO
Harrow stock will present 15 scientific studies across two major eye-care conferences, including 13 at the American Academy of Optometry and two at the American Academy of Ophthalmology, with the latter running from October 9-12, 2026. The presentations will cover various ophthalmic products like BYQLOVI, VEVYE, VERKAZIA, and FLAREX, showcasing Phase 3 data, safety data, and real-world evidence. Despite an increase in Q2 2026 revenue to USD 70.66 million, the company reported a GAAP net loss of USD 17.27 million and missed adjusted EPS consensus, indicating that commercial uptake needs to be weighed against rising expenses.
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on Harrow (HROW.US). This suggests a continued positive outlook from the firm regarding Harrow's stock performance.
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Harrow (Nasdaq: HROW) announced that 15 scientific abstracts featuring data from its ophthalmic portfolio will be presented at the American Academy of Optometry’s (AAOpt) Annual meeting and the American Academy of Ophthalmology’s (AAO) Annual Meeting in late 2026. The presentations will cover various conditions including dry eye disease, vernal keratoconjunctivitis, ocular inflammation, chronic blepharitis, and post-operative inflammation and pain, showcasing products like VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®. The research includes Phase 3 trial results, long-term safety data, real-world evidence, and systematic reviews, emphasizing Harrow's commitment to providing clinical evidence for informed treatment decisions.
Insider Confidence In These Growth Stocks For September 2026
This article highlights growth companies in the United States with high insider ownership, suggesting strong internal confidence and alignment with shareholder interests. It details three specific companies—Harrow (HROW), Intapp (INTA), and Frontier Group Holdings (ULCC)—showcasing their growth potential, recent strategic moves, and financial forecasts. The report also provides a list of the top 10 growth companies with significant insider ownership.
HROW6348836 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the HROW6348836 bond issued by Harrow, Inc. It outlines key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes information on the bond's fixed rate semi-annual coupon payments, with a rate of 8.63%, and a schedule of upcoming payouts.
Harrow (HROW) Short Interest & Short Float | Updated Sep 2026
Harrow (HROW) saw a 10.46% increase in short interest as of September 15, 2026, reaching 7.49 million shares, which represents 22.91% of its public float. The short interest ratio is 15.7 days to cover, indicating a significant amount of time would be needed for short sellers to close their positions. This rise in short interest suggests an increase in bearish sentiment among investors for Harrow.
Harrow, Inc. stock gains as market cap nears USD 1.2 billion
Harrow, Inc. (HROW) stock is trading strongly, with its market capitalization reported at approximately USD 1.22 billion as of September 20, 2026. The shares recently traded near USD 34.43 on Nasdaq, showing a mid-single-digit daily rise and significant gains over the past week and month. Analysts' 12-month target prices range from USD 42.00 to USD 76.00, suggesting potential for further upside despite the stock's volatility.
Is Harrow Inc (HROW) a Bargain After 3.2% Drop? GF Value Says Un
Harrow Inc (HROW) experienced a 3.2% stock drop, leading to its current price of $33.09. Despite this, GuruFocus's GF Value suggests the stock is undervalued at $43.74, indicating a potential investment opportunity. The company has a strong GF Score of 79/100, driven by high growth potential, but faces challenges in financial strength and significant insider selling.
Harrow at Cantor healthcare conference: long view, bigger eye-care bet
Harrow (HROW) outlined a long-term growth plan at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, focusing on a five-year strategy and reiterating its goal of $250 million quarterly revenue by calendar 2027. The company emphasized its shift towards "under-promising and over-delivering" and highlighted key growth drivers like VEVYE, IHEEZO, and the G-MELT program, alongside its ambition to become a full-service partner for ophthalmology practices. Despite competitive challenges and pricing fluctuations, Harrow expressed confidence in its product pipeline and strategic direction, particularly following the highly attractive acquisition of TYRVAYA.
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW)
Harrow, Inc. has appointed Andrew R. Boll, their current President and CFO, as the principal accounting officer, effective September 4, 2026. He succeeds Randall E. Pollard, who stepped down from the role. Boll will maintain both his existing positions and the new accounting officer duties without additional compensation, ensuring transparency in the company's financial leadership.
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor
Harrow Inc (HROW) shares increased by 5.6% to $39.05, placing the stock between its 52-week range and indicating an 8.8% undervaluation according to GuruFocus' GF Value of $42.84. Despite a strong GF Score of 77/100, driven by high growth potential, the company faces concerns regarding its unprofitability, negative cash flow, weak financial strength, and significant net selling by insiders. Investors are advised to exercise caution and conduct thorough due diligence before investing in the company.
Harrow to Participate in Three Investor Conferences in September
Harrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, announced its management will participate in three investor conferences in September 2026: the Cantor Global Healthcare Conference, Lake Street Capital Markets 10th Annual Best Ideas Growth Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company will engage in fireside chats and 1x1 investor meetings to discuss its business and strategy. Webcasts of the fireside chats will be available on Harrow's website.
Harrow to Participate in Three Investor Conferences in September
Harrow (Nasdaq: HROW) announced its participation in three investor conferences in September 2026. The company's management will engage in fireside chats and one-on-one meetings at the Cantor Global Healthcare Conference, Lake Street Capital Markets 10th Annual Best Ideas Growth Conference, and H.C. Wainwright 28th Annual Global Investment Conference. Webcasts of the fireside chats will be available on Harrow's website.
(HROW) as a Liquidity Pulse for Institutional Tactics
This article analyzes Harrow Health Inc. (HROW) using AI models to provide institutional trading strategies. Key findings indicate weak near and mid-term sentiment, with a neutral long-term outlook, and highlights an exceptional short setup. The analysis offers specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies across different time horizons.
ETFs Investing in Harrow, Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Harrow, Inc. (HROW) stocks, sorted by market value. It details various ETFs, including those focused on small-cap, health care, and pharmaceutical sectors, along with their issuers, management styles, expense ratios, and performance metrics, offering investors insights into diverse investment opportunities with HROW exposure.
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow Inc. announced positive results from a clinical study on its ocular anesthetic, IHEEZO, showing a significant 58% reduction in discomfort for patients undergoing intravitreal injections compared to proparacaine. This improvement in patient comfort could enhance compliance with eye treatments, according to William Blair analysts who maintain an Outperform rating on Harrow stock due to attractive long-term growth prospects.
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade
Harrow, Inc.'s Chief Scientific Officer, Amir Shojaei, sold 11,250 shares of common stock on August 14, 2026, after exercising employee stock options. The sale had an aggregate market value of approximately $450,000, and the Form 144 filing was delayed due to an administrative oversight. There were 37,487,850 shares of common stock outstanding at the time of the notice.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow (Nasdaq: HROW) announced positive results from a study showing that its ophthalmic gel, IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, significantly reduced patient-reported discomfort during and after intravitreal injections. Patients experienced approximately 58% less discomfort in the IHEEZO-treated eye compared to those treated with proparacaine, with the largest differences observed immediately post-injection. These findings suggest IHEEZO could improve the patient experience for the millions of intravitreal injections performed annually.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow (Nasdaq: HROW) announced positive results from a study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% in patients undergoing bilateral intravitreal injections. The study showed that patients reported approximately 58% less overall discomfort in the IHEEZO-treated eye compared to the eye treated with proparacaine ophthalmic solution 0.5%. These findings suggest IHEEZO offers a significant improvement in patient comfort following a common ophthalmic procedure.
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) faces a significant challenge to meet its full-year revenue guidance of $350-$365 million after a first half that fell short. Despite strong product momentum with IHEEZO, VEVYE, and TRIESENCE, and the pending acquisition of TYRVAYA, the company needs to generate $235-$250 million in the second half compared to $115 million in the first half. Wall Street remains skeptical, with high short interest and a substantial forward P/E ratio.
Harrow, Inc.: Harrow Health, Inc. Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow Health, Inc. announced positive results from a study evaluating IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia during intravitreal injections. The study showed statistically significant reductions in patient-reported discomfort with IHEEZO compared to proparacaine ophthalmic solution 0.5% at all measured time points. These findings suggest IHEEZO can improve patient comfort for the millions of intravitreal injections performed annually.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow announced positive results from a study showing that its IHEEZO® ophthalmic gel significantly reduced patient-reported discomfort following intravitreal injections. Patients experienced approximately 58% less discomfort with IHEEZO compared to proparacaine, especially immediately after injection. This finding is significant for retina specialists and patients undergoing frequent injections, as it highlights IHEEZO's potential to improve the patient experience.
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort
Harrow (Nasdaq: HROW) announced positive results from a study showing its IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% significantly reduced patient-reported discomfort during intravitreal injections. In a 50-patient, contralateral-eye study, IHEEZO-treated eyes experienced approximately 58% less discomfort compared to eyes treated with proparacaine 0.5%, with statistically significant differences observed at all post-injection assessments over 24 hours. This data suggests IHEEZO offers a measurable improvement in patient comfort for a common ophthalmic procedure.
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) faces a significant challenge to meet its full-year revenue guidance of $350 million to $365 million after a softer first half. Despite strong product momentum in IHEEZO, VEVYE, and TRIESENCE, and an upcoming acquisition of TYRVAYA, the company needs to generate $235 million to $250 million in the second half, compared to $115 million in the first. Wall Street remains skeptical, with high short interest and a forward P/E ratio that already prices in substantial growth.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow (Nasdaq: HROW) announced positive results from a study showing that IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% significantly reduced patient-reported discomfort after intravitreal injections. Patients experienced approximately 58% less discomfort in the IHEEZO-treated eye compared to the eye treated with proparacaine, with the largest differences noted immediately post-injection. This data supports IHEEZO's clinical profile for improving patient comfort during a frequently performed ophthalmic procedure.
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?
Harrow (HROW) reaffirmed its 2026 revenue guidance of US$350 million to US$365 million despite reporting higher sales but a wider net loss in Q2. The stock has seen a significant gain over the past three months but a recent pullback. A narrative suggests Harrow is 42.2% undervalued, with a fair value of $68.38, driven by growing demand for its ophthalmic drugs, though potential risks like reliance on key products and drug pricing pressure exist.
Harrow And 2 Other Growth Stocks Insiders Are Betting On
This article highlights three US growth companies with significant insider ownership: Harrow (HROW), Hennessy Capital Investment VII (HVII), and Alphatec Holdings (ATEC). Despite some current losses or early-stage operations, these companies are projected to have strong earnings and revenue growth, making them appealing to investors looking for potential long-term value. The report emphasizes that high insider ownership can signal confidence in future expansion and value creation.
Harrow CSO Amir Shojaei sells $450,000 in company stock
Amir Shojaei, Chief Scientific Officer at HARROW, INC., sold 11,250 shares of company stock worth $450,000 on August 14, 2026. This transaction involved the exercise of stock options to cover costs, with Shojaei acquiring and immediately selling shares, resulting in no retained shares from this specific option exercise. Despite this, Shojaei still holds 18,750 derivative securities, and InvestingPro analysis suggests HROW is undervalued with a Strong Buy consensus.
Harrow CSO Amir Shojaei sells $450,000 in company stock
Amir Shojaei, Chief Scientific Officer at HARROW, INC. (NASDAQ:HROW), sold 11,250 shares of company stock for $450,000 after exercising stock options. The sale was a broker-assisted transaction to cover the exercise price and associated costs, with Shojaei not retaining any of the acquired shares. This transaction follows recent news of Harrow Health reporting a wider-than-expected loss in Q2 2026, despite increased revenue.
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW
Rice Hall James & Associates LLC has acquired a new position in Harrow, Inc. (NASDAQ:HROW), purchasing 387,545 shares valued at approximately $16.46 million, representing 1.04% of the company. Institutional investors now own 72.76% of Harrow, while insider Amir Shojaei recently sold 11,250 shares worth $450,000. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $69.43, even as the company reported a quarterly loss that missed expectations.
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy?
Harrow, Inc. reported second-quarter revenue of US$70.66 million and a net loss of US$17.27 million, while reiterating its 2026 revenue guidance of US$350 million to US$365 million. The company recently agreed to acquire TYRVAYA nasal spray for up to US$100 million to expand its dry eye disease franchise, complementing its existing VEVYE offering. This acquisition, alongside the reaffirmed guidance, could redefine Harrow's investment narrative, although it also highlights the challenge of achieving sustained profitability while integrating new acquisitions.
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares
Harrow insider Amir Shojaei sold 11,250 shares of the company's stock for $450,000, reducing his ownership by 50%. This sale occurred on August 14th, with the stock trading down 1.4% to $39.47 on Monday. Despite missing earnings per share estimates, the company's revenue slightly exceeded expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $69.43.
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History
This article provides the historical holding data of Harrow Inc (HROW) by Royce Micro-Cap Fund, showing no recent buys or sells. It also lists several related articles concerning Harrow Inc's financial performance, stock valuation, and earnings call highlights from Q2 2026. The content is hosted on GuruFocus.com, a financial data and analysis platform.
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"
Wall Street Zen has upgraded Harrow (NASDAQ:HROW) from "sell" to "hold," though overall analyst sentiment remains a "Moderate Buy" with a target of $69.43. This comes as Harrow reported a quarterly loss that missed estimates despite slightly exceeding revenue expectations. Institutional investors hold a significant portion of the company's stock, and an insider recently purchased shares, while potential growth from new product commercialization is balanced against lowered earnings forecasts and ongoing profitability concerns.
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Harrow, Inc. (NASDAQ:HROW) recently released its second-quarter results, showing revenues in line with expectations at US$71m, but statutory losses increased to US$0.46 per share. Following these results, analysts have updated their forecasts, predicting revenues of US$350.7m for 2026 but cutting EPS estimates significantly to US$0.14 per share, indicating a more bearish outlook. Despite the reduced earnings forecast, the consensus price target remains steady at US$67.50, suggesting analysts don't foresee a lower stock price due to the earnings revision.
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Harrow, Inc. (NASDAQ:HROW) recently released its second-quarter results, showing revenues in line with expectations at US$71m but increased statutory losses of US$0.46 per share. Analysts have updated their forecasts, maintaining revenue predictions for 2026 at US$350.7m but significantly cutting EPS estimates from US$0.23 to US$0.14. Despite the lowered earnings outlook, the consensus price target remains steady at US$67.50, suggesting analysts believe the lower forecast earnings will not immediately impact the stock price.
Q2 2026 Harrow Inc Earnings Call Transcript
Harrow Inc. reported its Q2 2026 earnings, with revenues reaching $70.7 million, an 11% year-over-year increase, driven by strong performances in IHISO, Vevi, and Triessence products. Despite first-half revenues being lighter than expected due to Vevi's net revenue impact and IHISO inventory normalization, the company reiterated its full-year 2026 revenue guidance of $350-$365 million and adjusted EBITDA of $80-$100 million. The pending Tervaya acquisition is anticipated to be financially accretive, adding over $30 million in revenue by 2027, although it will also increase SG&A expenses.
HROW Reiterated by BTIG -- Price Target Maintained at $63
BTIG has reiterated its "Buy" rating for Harrow Inc (HROW), maintaining a price target of $63.00, which suggests the stock is currently undervalued by approximately 12.8% according to GuruFocus's GF Value™ of $44.53. Despite being unprofitable with a high forward P/E, the company shows positive insider buying activity and a moderate GF Score™ of 67/100, indicating strengths in valuation and profitability. Four gurus hold positions in HROW, with one increasing their stake.
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts
Harrow, Inc. (NASDAQ:HROW) has received an average rating of "Moderate Buy" from analysts, with eight out of eleven recommending a "buy" and an average 12-month price target of $69.43, significantly higher than its current price of $40.70. Despite falling short on profitability in recent earnings with a $0.34 loss per share against an expected $0.18 loss, the company reported revenues slightly above estimates. Insiders and institutional investors maintain substantial holdings, with recent share purchases by the CFO and a director indicating continued confidence.
Harrow Achieves Q2 Revenue Growth, Reiterates 2026 Full-Year Financial Guidance
Harrow announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $70.7 million, a 60 percent sequential increase. The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA. Key developments include the commercial launch of Byooviz and the acquisition of Tyrvaya, positioning Harrow for accelerated growth.
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story
Harrow, Inc. (HROW) reported a swing from profit to a net loss in Q2 2026, despite rising sales, with net loss deepening to US$44.87 million over the first six months of 2026. This shift challenges the company's investment narrative, which relies on its expanding ophthalmic portfolio achieving sustainable profitability. The new partnership for the BYOOVIZ biosimilar is a key element that could help absorb elevated costs, though investors are cautioned about growing operating expenses.
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M
Harrow, Inc. (HROW) announced its Q2 financial results, reporting revenue of $70.7 million. This figure exceeded the FactSet estimate of $70.4 million. The flash earnings report highlights a positive performance for the company in the second quarter.
Harrow: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Harrow. As the provided content is minimal, no further details can be extracted regarding the financial performance or other specific results.
Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS
Harrow (NASDAQ:HROW) reported a quarterly EPS of ($0.46), missing analysts' consensus of ($0.18) by $0.28, despite revenue of $70.66 million slightly exceeding expectations. Shares of HROW traded up 0.6% following the announcement. The company has a "Moderate Buy" consensus rating from analysts, with insider buying activity also noted from the CFO and a director.
Harrow, Inc. (HROW) stock falls on Q2 2026 Earnings
Harrow, Inc. (HROW) reported its Q2 2026 earnings, with revenue increasing by 10.9% to $70.7 million, but the company faced pressure on profitability. The operating loss widened to $11.0 million, and the net loss attributable to common shareholders was $17.3 million, resulting in a diluted loss per share of $0.46 against an estimated $0.18. Following the earnings report, the stock declined by 1.75% after hours.
BRIEF-Harrow Inc Q2 Gross Margin 71%
Harrow Inc. reported a Q2 gross margin of 71%. The article is a brief financial update and directs readers to TradingView for full access to the Reuters article and other news sources.
Harrow Announces Second Quarter 2026 Financial Results
Harrow (Nasdaq: HROW) announced its second-quarter 2026 financial results, reporting a quarterly revenue of $70.7 million, a 60% sequential increase and 11% year-over-year increase. The company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. Key product VEVYE® saw significant growth, and the company completed the acquisition of TYRVAYA® and launched BYOOVIZ®, strengthening its ophthalmic disease management portfolio.
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) reported a Q2 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.23 loss, and revenues of $70.66 million, also below estimates. The company's shares have underperformed the S&P 500 this year, and its current Zacks Rank is #3 (Hold), indicating expected performance in line with the market. Investors will be looking to management's commentary and future estimate revisions for insights into the stock's direction.
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback?
Harrow Health Inc. is set to report its second-quarter earnings, with analysts expecting a significant rebound in revenue and a narrowed loss after a disappointing first quarter. Despite unanimous "buy" ratings from analysts and a substantial implied upside, investors are keenly watching if the company can deliver on its 60% sequential revenue jump, improve its path to profitability, and demonstrate strong product portfolio momentum. The results will determine if Harrow can regain its footing in the competitive and growing ophthalmic drugs market.
HARROW HEALTH Q2 2026 Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More
This article previews HARROW HEALTH's (HROW) Q2 2026 earnings, expected on August 10th, with analysts forecasting $71.7 million in revenue and an EPS of -$0.18. It details recent insider trading activity, including both purchases and sales, and highlights significant hedge fund movements, with 83 institutional investors increasing and 110 decreasing their positions. The article also provides an overview of recent analyst ratings and price targets for HROW.
